Navigation Links
DARA BioSciences to Present at the ROTH Growth Stock Conference
Date:2/4/2008

RALEIGH, N.C., Feb. 4 /PRNewswire/ -- DARA BioSciences, Inc. today announced that the Company will present at the ROTH 20th Annual Growth Stock Conference in Dana Point, CA on Tuesday, February 19, 2008 at 3:30pm Pacific.

Interested parties can access a live web cast of the presentation at http://www.darabiosciences.com. A replay of the presentation will be available at the same location.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders.

Additional Information and Where to Find It

On October 9, 2007, DARA entered into a definitive agreement to merge with Point Therapeutics, Inc. (Nasdaq: POTP) ("Point"). Pursuant to the merger agreement, DARA will merge with DP Acquisition Corp., a newly-formed subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of Point. After giving effect to the merger, DARA stockholders will hold 96.4% of the combined company's outstanding shares of common stock on a fully-diluted basis, and Point will change its name to DARA BioSciences, Inc. and be based in Raleigh, North Carolina. For information regarding the proposed merger, please refer to the registration statement on Form S-4, which contains a joint p
'/>"/>

SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (Monday, June 17, 2013) A million electric cars could ... the decade with the help of research by the United ... University of Waterloo. , Professor Zhongwei Chen is part of ... to develop non-precious materials to replace the expensive platinum catalysts ... the adoption of fuel cells in vehicles is the cost ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
(Date:6/18/2013)... The human skin is the largest organ, yet ... body part. Similar to the liver, or heart, the skin ... and grow. Recent reports from the mankatofreepress.com explained how caring ... important as other life supporting organs. The article suggests several ... reproduction, increase the appearance of skin, and fight off acne ...
(Date:6/18/2013)... , June 18, 2013 ... using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental ... implants. A common problem encountered when patients have ... of sufficient bone volume to house the implant. Consequently there ... bone substitute until the natural bone regenerates. The bone substitute ...
Breaking Biology Technology:US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3
... CITY, June 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... global biopharmaceutical company focused on endocrine therapy and ... previously announced registered direct offering of US$10 million ... share purchase warrants to certain institutional investors. AEterna ...
... June 24 International Products Corporation,s ( ... performing filter membrane compatibility and performance ... the ability to evaluate any type of membrane media, from ... President, Kathy Wyrofsky. "Our goal is to be able ...
... ... that it provided the Helsinn Group with the transaction advisory support for the successful ... on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 . ... Oxford, UK ...
Cached Biology Technology:AEterna Zentaris Receives US$10 Million from Institutional Investors 2AEterna Zentaris Receives US$10 Million from Institutional Investors 3International Products Corp.'s Lab Offers Filter Membrane Compatibility and Studies 2PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group 2
(Date:6/18/2013)... been awarded a $394,300 grant from the Tarrant ... flow in the new facilities of the 150-mile ... associate professor of civil engineering, will investigate the ... the water in an effort to eliminate biological ... Adding monochloramine is widely practiced throughout the United ...
(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... demonstrated the role of a gene important to the ... requires coordination of differentiation of immature neural cells with ... Until now, the mechanisms regulating these distinct cellular activities ... be published in the Feb. 15 issue of Development. ...
... hunting among chimpanzees is a group effort, key males, known ... are more likely to initiate a hunt, and hunts rarely ... The findings, which appear in the current issue of Animal ... to hunt for food, and how individual variation among chimpanzees ...
... more sensitive and more accurate than conventional imaging methods ... to a UCLA study that is among the first ... study has important implications for patients. If conventional imaging ... that in fact are working and study participants may ...
Cached Biology News:Trainor Lab characterizes gene essential for prenatal development of nervous system 2Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Positron emission tomography superior to standard evaluation tools in measuring treatment response 2Positron emission tomography superior to standard evaluation tools in measuring treatment response 3
... Microarrays designed for proteomic scale kinase ... activities, and drug discovery research built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive Protein Kinase Substrate - Peptide ...
... Western blotting is a commonly used technique ... protein samples are electrophoresed on SDS-PAGE and ... or nylon, where they are probed with ... which allow reuse of Southern and Northern ...
... for immunological studies, vaccine development, and ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive Epitope Peptide ... Content Probe content is completely ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: